Published in Rev Diabet Stud on August 10, 2004
Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus. Nutr Metab (Lond) (2010) 0.95
Metformin treatment in hyperglycemic critically ill patients: another challenge on the control of adverse outcomes. Iran J Pharm Res (2011) 0.76
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes (2001) 9.67
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med (1995) 6.51
Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med (1999) 5.65
Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med (1998) 4.40
Metformin in non-alcoholic steatohepatitis. Lancet (2001) 3.63
The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med (1994) 2.08
Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med (1997) 1.69
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44) Diabetes Care (1999) 1.32
An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med (1997) 1.22
Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care (1993) 1.21
Incidence of non-insulin-dependent diabetes mellitus and its risk factors in Japanese-Americans living in Hawaii and Los Angeles. Diabet Med (1996) 1.19
Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care (1993) 1.17
Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract (2001) 1.03
Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol (1993) 1.00
Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int J Obes Relat Metab Disord (1997) 0.89
Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care (1990) 0.87
Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med (1994) 0.84
The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabet Med (1988) 0.82
Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo. Diabetes Metab (1996) 0.81
Role of metformin in treatment of diabetes mellitus. Diabetes Care (1987) 0.80
Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia. Eur J Clin Invest (1994) 0.79
Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care (1996) 0.79
Effects of the treatment with acarbose in elderly overweight type 2 diabetic patients in poor glycemic control with oral hypoglycemic agents or insulin. Arch Gerontol Geriatr (2000) 0.78
Oral agent therapy in the treatment of type 2 diabetes. Diabetes Care (1999) 0.77
The minimum dose of acarbose suppresses triglyceride concentration in remnant-like particles from fasted diabetic subjects. Horm Metab Res (1996) 0.77
Acarbose treatment of sulfonylurea-treated non-insulin dependent diabetics. A double-blind cross-over comparison of an alpha-glucosidase inhibitor with metformin. Diabete Metab (1984) 0.77
Hypolipidemic effects of metformin in hyperprebetalipoproteinemia. Diabete Metab (1976) 0.77
SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet (2008) 8.63
Anatomic and visual outcomes after indocyanine green-assisted peeling of the retinal internal limiting membrane in idiopathic macular hole surgery. Am J Ophthalmol (2004) 4.57
Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population. Diabetes (2007) 3.24
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet (2008) 2.89
A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nat Genet (2010) 2.81
Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension (2010) 2.37
Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) (2002) 2.26
Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest (2004) 2.24
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood (2007) 2.23
Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens Res (2010) 2.18
Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care (2003) 2.06
Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism (2009) 1.86
Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens (2011) 1.75
Importance of rostral ventrolateral medulla neurons in determining efferent sympathetic nerve activity and blood pressure. Hypertens Res (2011) 1.72
Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab (2004) 1.69
Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab (2008) 1.67
Dimethylarginine dimethylaminohydrolase 2 increases vascular endothelial growth factor expression through Sp1 transcription factor in endothelial cells. Arterioscler Thromb Vasc Biol (2006) 1.62
Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension (2003) 1.59
Beta cell dysfunction and its clinical significance in gestational diabetes. Endocr J (2010) 1.58
Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese. Carcinogenesis (2008) 1.57
Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. J Hypertens (2014) 1.56
PPAR(gamma)2 gene Pro12Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population. Metabolism (2002) 1.56
Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension (2008) 1.54
Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine phosphatase gene (PTPN22): association between a promoter polymorphism and type 1 diabetes in Asian populations. Am J Med Genet A (2006) 1.54
Genome-wide association study of pancreatic cancer in Japanese population. PLoS One (2010) 1.50
Enterovirus infection, CXC chemokine ligand 10 (CXCL10), and CXCR3 circuit: a mechanism of accelerated beta-cell failure in fulminant type 1 diabetes. Diabetes (2009) 1.50
Role of endothelium-derived hyperpolarizing factor in ACE inhibitor-induced renal vasodilation in vivo. Hypertension (2004) 1.49
Expression of the Na+/H+ exchanger regulatory protein family in genetically hypertensive rats. J Hypertens (2004) 1.49
Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Hypertens Res (2010) 1.47
Monosynaptic excitatory connection from the rostral ventrolateral medulla to sympathetic preganglionic neurons revealed by simultaneous recordings. Hypertens Res (2008) 1.47
T-cell-mediated autoimmunity may be involved in fulminant type 1 diabetes. Diabetes Care (2002) 1.45
Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury. Hypertens Res (2007) 1.45
Cloning and characterization of a novel gene promoting ureteric bud branching in the metanephros. Kidney Int (2003) 1.45
High-density association study and nomination of susceptibility genes for hypertension in the Japanese National Project. Hum Mol Genet (2007) 1.44
Association of blood pressure control and metabolic syndrome with cardiovascular risk in elderly Japanese: JATOS study. Am J Hypertens (2011) 1.44
Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial. Circ J (2009) 1.40
Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan. Hypertens Res (2006) 1.39
Genome-wide association study identifies HLA-DP as a susceptibility gene for pediatric asthma in Asian populations. PLoS Genet (2011) 1.38
Ca2+ channel subtypes and pharmacology in the kidney. Circ Res (2007) 1.38
Genome-wide association study identifies a novel locus contributing to type 2 diabetes susceptibility in Sikhs of Punjabi origin from India. Diabetes (2013) 1.36
Correlation between serum resistin level and adiposity in obese individuals. Obes Res (2003) 1.36
Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ Res (2004) 1.33
Genome-wide association study identifies three novel loci for type 2 diabetes. Hum Mol Genet (2013) 1.28
Association of type 1 diabetes with two Loci on 12q13 and 16p13 and the influence coexisting thyroid autoimmunity in Japanese. J Clin Endocrinol Metab (2008) 1.24
A single-nucleotide polymorphism in ANK1 is associated with susceptibility to type 2 diabetes in Japanese populations. Hum Mol Genet (2012) 1.23
Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int J Cancer (2005) 1.22
Rho-kinase as a molecular target for insulin resistance and hypertension. FASEB J (2005) 1.22
Genetic variations in the gene encoding TFAP2B are associated with type 2 diabetes mellitus. J Hum Genet (2005) 1.21
Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int (2003) 1.21
Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism (2002) 1.18
A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer. Gastroenterology (2010) 1.17
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer (2006) 1.17
Irinotecan for children with relapsed solid tumors. Pediatr Hematol Oncol (2006) 1.17
The association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease: a multicenter collaborative study in Japan. J Clin Endocrinol Metab (2005) 1.17
CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis. J Immunol (2004) 1.16
Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. Carcinogenesis (2010) 1.15
Extracellular matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and migration. Circ Res (2004) 1.13
Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J (2011) 1.11
Intrarenal injection of bone marrow-derived angiogenic cells reduces endothelial injury and mesangial cell activation in experimental glomerulonephritis. J Am Soc Nephrol (2005) 1.11
Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens (2005) 1.07
Association of new loci identified in European genome-wide association studies with susceptibility to type 2 diabetes in the Japanese. PLoS One (2011) 1.07
High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men. Metabolism (2007) 1.04
The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Hypertens Res (2008) 1.03
Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis (2005) 1.03
Ubc9 and Protein Inhibitor of Activated STAT 1 Activate Chicken Ovalbumin Upstream Promoter-Transcription Factor I-mediated Human CYP11B2 Gene Transcription. J Biol Chem (2004) 1.03
High-molecular-weight adiponectin is a predictor of progression to metabolic syndrome: a population-based 6-year follow-up study in Japanese men. Metabolism (2009) 1.02
Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res (2005) 1.02
Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res (2004) 1.02
Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice. J Immunol (2003) 1.02
ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev Cardiovasc Ther (2008) 1.01
FHL2, UBC9, and PIAS1 are novel estrogen receptor alpha-interacting proteins. Endocr Res (2004) 1.00
Vessel- and vasoconstrictor-dependent role of rho/rho-kinase in renal microvascular tone. J Vasc Res (2003) 1.00
Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood (2010) 0.99
Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res (2004) 0.98
Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension. Clin Exp Hypertens (2006) 0.98
The combination therapy of hypertension to prevent cardiovascular events (COPE) trial: rationale and design. Hypertens Res (2005) 0.98
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther (2008) 0.98
Gene transfer of truncated IkappaBalpha prevents tubulointerstitial injury. Kidney Int (2003) 0.98
Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Hypertens Res (2012) 0.98
Transient receptor potential channels in rat renal microcirculation: actions of angiotensin II. Kidney Int (2002) 0.97
Electrophysiological properties of rostral ventrolateral medulla neurons in angiotensin II 1a receptor knockout mice. Hypertension (2005) 0.96
Role of Rho-kinase and p27 in angiotensin II-induced vascular injury. Hypertension (2005) 0.96
Relationships between serum soluble leptin receptor level and serum leptin and adiponectin levels, insulin resistance index, lipid profile, and leptin receptor gene polymorphisms in the Japanese population. Metabolism (2004) 0.96
Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. J Pharmacol Sci (2005) 0.95
Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats. Nephron (2002) 0.95
Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J Biol Chem (2006) 0.95